Literature DB >> 19016722

Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia.

Guy Pratt1, Stephen Harding, Roger Holder, Chris Fegan, Chris Pepper, David Oscier, Anne Gardiner, Arthur R Bradwell, Graham Mead.   

Abstract

The measurement of immunoglobulin serum free light chains (sFLC) has prognostic significance in plasma cell dyscrasias but its role in chronic lymphocytic leukaemia (CLL) is unknown. This retrospective study from three UK hospitals analysed sFLC in 181 untreated/pre-treatment CLL patients and 78 treated CLL patients, with samples taken later in their disease. An abnormal sFLC ratio was significantly associated with poor overall survival for the 181 untreated/pre-treatment patients (P = 0.0001) and for all patients (P = 0.002), irrespective of cause of death. Using multivariate analysis (n = 194), four independent prognostic variables for overall survival were identified namely Zap-70 (P = 0.0001), beta2M (P = 0.01), IGHV mutation status (P = 0.017) and an abnormal sFLC ratio (P = 0.024). For CLL patients with unmutated IGHV genes, elevated kappa/lambda ratios were adversely prognostic. For patients with mutated IGHV genes, reduced kappa/lambda ratios were adversely prognostic and associated with the poor prognostic IGHV3-21, IGHV3-48 and IGHV3-53 subgroups, suggesting an abnormal sFLC ratio may reflect biological subgroups within CLL. Abnormal sFLC ratios need to be studied prospectively in CLL patients and the biological rationale for their abnormality investigated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19016722     DOI: 10.1111/j.1365-2141.2008.07456.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.

Authors:  D Rizzo; J Chauzeix; F Trimoreau; J B Woillard; F Genevieve; A Bouvier; J Labrousse; C Poli; E Guerin; N Dmytruk; L Remenieras; J Feuillard; N Gachard
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

2.  Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia.

Authors:  Matthew J Maurer; James R Cerhan; Jerry A Katzmann; Brian K Link; Cristine Allmer; Clive S Zent; Timothy G Call; Kari G Rabe; Curtis A Hanson; Neil E Kay; Susan L Slager; Thomas E Witzig; Tait D Shanafelt
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

3.  Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.

Authors:  Matthew J Maurer; Ivana N M Micallef; James R Cerhan; Jerry A Katzmann; Brian K Link; Joseph P Colgan; Thomas M Habermann; David J Inwards; Svetomir N Markovic; Stephen M Ansell; Luis F Porrata; Patrick B Johnston; Grzegorz S Nowakowski; Carrie A Thompson; Mamta Gupta; Sergei I Syrbu; Paul J Kurtin; William R Macon; Daniel A Nikcevich; Thomas E Witzig
Journal:  J Clin Oncol       Date:  2011-03-07       Impact factor: 44.544

4.  Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; Terry M Therneau; Colin L Colby; Raynell J Clark; Graham P Mead; Shaji Kumar; L Joseph Melton; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

5.  Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study.

Authors:  Huei-Ting Tsai; Neil E Caporaso; Robert A Kyle; Jerry A Katzmann; Angela Dispenzieri; Richard B Hayes; Gerald E Marti; Maher Albitar; Paolo Ghia; S Vincent Rajkumar; Ola Landgren
Journal:  Blood       Date:  2009-10-14       Impact factor: 22.113

6.  Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia.

Authors:  Lesley A Anderson; Ola Landgren; Eric A Engels
Journal:  Br J Haematol       Date:  2009-09-01       Impact factor: 6.998

7.  Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees.

Authors:  Martha J Glenn; Michael J Madsen; Ethan Davis; Cassandra D Garner; Karen Curtin; Brandt Jones; Justin A Williams; Michael H Tomasson; Nicola J Camp
Journal:  Blood Cancer J       Date:  2019-02-26       Impact factor: 11.037

8.  Prognostic significance of serum free light chains in chronic lymphocytic leukemia.

Authors:  Katerina Sarris; Dimitrios Maltezas; Efstathios Koulieris; Vassiliki Bartzis; Tatiana Tzenou; Sotirios Sachanas; Eftychia Nikolaou; Anna Efthymiou; Katerina Bitsani; Maria Dimou; Theodoros P Vassilakopoulos; Marina Siakantaris; Maria K Angelopoulou; Flora Kontopidou; Panagiotis Tsaftaridis; Nikolitsa Kafasi; Gerasimos A Pangalis; Panayiotis P Panayiotidis; Stephen Harding; Marie-Christine Kyrtsonis
Journal:  Adv Hematol       Date:  2013-10-29

9.  Serum soluble TACI, a BLyS receptor, is a powerful prognostic marker of outcome in chronic lymphocytic leukemia.

Authors:  Marie-Christine Kyrtsonis; Katerina Sarris; Efstathios Koulieris; Dimitrios Maltezas; Eftychia Nikolaou; Maria K Angelopoulou; Vassiliki Bartzis; Tatiana Tzenou; Maria Dimou; Mariana P Siakandaris; Nora A Viniou; Sotirios Sachanas; Christina Kalpadakis; Petros P Sfikakis; Gerassimos A Pangalis; Panayiotis Panayiotidis
Journal:  Biomed Res Int       Date:  2014-08-06       Impact factor: 3.411

10.  Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Authors:  Alyssa I Clay-Gilmour; Abdul R Rishi; Lynn R Goldin; Alexandra J Greenberg-Worisek; Sara J Achenbach; Kari G Rabe; Matthew J Maurer; Neil E Kay; Tait D Shanafelt; Timothy G Call; J Brice Weinberg; Nicola J Camp; James R Cerhan; Jose Leis; Aaron Norman; David L Murray; S Vincent Rajkumar; Neil E Caporaso; Ola Landgren; Mary L McMaster; Susan L Slager; Celine M Vachon
Journal:  Blood Cancer J       Date:  2019-08-05       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.